All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
indanocine
Known as:
indanosine
Â
Â
Topic mentions per year
Topic mentions per year
2000-2012
0
1
2
3
2000
2012
Related topics
Related topics
1 relation
Broader (1)
Indans
Related mentions per year
Related mentions per year
1998-2012
1990
2000
2010
2020
indanocine
Indans
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Kinetic stabilization of microtubule dynamics by indanocine perturbs EB1 localization, induces defects in cell polarity and inhibits migration of MDA-MB-231 cells.
Sonia Kapoor
,
Dulal Panda
Biochemical pharmacology
2012
Cell motility is an essential aspect of metastatic spread of cancer. Microtubule-targeted agents exhibit anti-metastatic…Â
(More)
Is this relevant?
2009
2009
Binding of indanocine to the colchicine site on tubulin promotes fluorescence, and its binding parameters resemble those of the colchicine analogue AC.
Lalita Das
,
Suvroma Gupta
,
Dipak Dasgupta
,
Asim Poddar
,
Mark E Janik
,
Bhabatarak Bhattacharyya
Biochemistry
2009
Indanocine, a synthetic indanone, has shown potential antiproliferative activity against several tumor types. It is different…Â
(More)
Is this relevant?
2001
2001
Biochemical genetic analysis of indanocine resistance in human leukemia.
Xiqi Hua
,
Davide Genini
,
+5 authors
Lorenzo M Leoni
Cancer research
2001
Indanocine is a potent tubulin-binding drug that is cytotoxic to multidrug-resistant cancer cell lines. We demonstrated that…Â
(More)
Is this relevant?
2000
2000
Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells.
Lorenzo M Leoni
,
Ernest Hamel
,
+4 authors
Daniel Carson
Journal of the National Cancer Institute
2000
BACKGROUND Certain antimitotic drugs have antitumor activities that apparently result from interactions with nontubulin…Â
(More)
Is this relevant?
2000
2000
Tubulin/microtubules: still a promising target for new chemotherapeutic agents.
Paraskevi Giannakakou
,
Dan L. Sackett
,
Tito Fojo
Journal of the National Cancer Institute
2000
Most investigators would agree that the ideal chemotherapeutic agent should be 1) directed at a validated target; 2) potent…Â
(More)
Is this relevant?
2000
2000
Tubulin as a target for anticancer drugs.
Erwin von Angerer
Current opinion in drug discovery & development
2000
Nature provides a large spectrum of agents that either inhibit the polymerization of tubulin or prevent the disassembly of…Â
(More)
Is this relevant?